Lupin Faces USFDA Form 483 Issuance Amid Somerset Facility Compliance Scrutiny
Major pharmaceutical company Lupin has confirmed that a regulatory filing revealed the US Food and Drug Administration (USFDA) issued a 'Form 483' carrying three observations regarding its manufacturing facility in Somerset, New Jersey. The findings follow a recent inspection conducted by the US health regulator.Lupin stated that the detailed inspection took place at the Somerset location this week, spanning from April 13 to April 17. The company confirmed that the inspection concluded with the issuance of the Form 483, which detailed three specific observations.
The drug maker asserted its commitment to rectifying these observations and pledged to respond to the USFDA within the stipulated regulatory timeframe. Furthermore, Lupin reiterated its dedication to maintaining compliance with Current Good Manufacturing Practices (cGMP) standards across its global operations.
Understanding the Form 483 Compliance Notice
The Form 483 is a standard regulatory document issued to a company’s management at the conclusion of an inspection. It flags conditions observed by investigators that may potentially violate the Food, Drug and Cosmetic (FD&C) Act and associated regulations.The regulatory scrutiny is not unprecedented for the company. Earlier this year, the USFDA had inspected Lupin’s manufacturing facility in Ankleshwar, India, between March 2 and March 7. That inspection also resulted in a Form 483, which carried two observations.
Despite these findings, the company has repeatedly stated that it will address the observations and respond within the required timelines while upholding strict compliance with cGMP standards.
Market Reaction After Regulatory Findings
On Friday, shares of Lupin ended the trading day at Rs 2,322.50, marking a slight decrease of 0.19 per cent on the National Stock Exchange (NSE).Despite the regulatory developments, the pharma stock remains within a defined trading range. Investors noted that the stock had previously touched a 52-week high of Rs 2,377.60 and recorded a 52-week low of Rs 1,836.80 on the exchange.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.